Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease

Journal of Clinical Oncology

Volumn 15, Issue 6, 1997, Pages 2275-2287

  Loeffler, M ^a   Diehl, V ^a   Pfreundschuh, M ^a   Ruhl U ^a   Hasenclever, D ^a   Nisters Backes, H ^a   Sieber, M ^a   Tesch, H ^a   Franklin, J ^a   Geilen, W ^a   Bartels, H ^a   Cartoni, C ^a   Dolken G ^a   Enzian, J ^a   Fuchs, R ^a   Gassmann, W ^a   Gerhartz, H ^a   Hagen Aukamp, U ^a   Hiller, E ^a   Hinkelbein, H ^a   Hinterberger, W ^a   Kirchner, H ^a   Koch, P ^a   Kruger B ^a   Schwarze, E W ^a   more..

^a German Hodgkin's Lymphoma Study Group   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; DOSE RESPONSE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HODGKIN DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LAPAROTOMY; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM MASS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZATION; RISK FACTOR;

EID: 17544388313     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.6.2275     Document Type: Article

References (25)

1. Loeffler M, Mauch P, Laclennan K, et al: Review on prognostic factors on Hodgkin's disease. Ann Oncol 3:563-566, 1992 (suppl 4)
2. Mauch P, Goodman R, Hellman S: The significance of mediastinal involvement in early stage Hodgkin's disease. Cancer 42:1039-1045, 1978
3. Lee CKK, Bloomfield CD, Goldman AI, et al: Prognostic significance of mediastinal involvement in Hodgkin's disease treated with curative radiotherapy. Cancer 46:2403-2409, 1980
4. Tubiana M, Henry-Amar M, Hayat M, et al: Prognostic significance of the number of involved areas in the early stages of Hodgkin's disease. Cancer 54:885-894, 1984
5. Tubiana M, Henry-Amar M, Van Der Wert-Messing B, et al: A multivariate analysis of prognostic factors in early stage Hodgkin's disease. Int J Radiat Oncol Biol Phys 11:23-30, 1985
6. Gobbi PG, Cavalli C, Frederico M, et al: Hodgkin's disease prognosis: A directly predictive equation. Lancet 3:675-678, 1988
7. Loeffler M, Pfreundschuh M, Hasenclever D, et al: Prognostic risk factors in advanced Hodgkin's lymphoma. Report of the German Hodgkin Study Group. Blut 56:273-281, 1988
8. Tubiana M, Henry-Amar M, Burgers MV, et al: Prognostic significance of erythrocyte sedimentation rate in clincal stages I-II of Hodgkin's disease. J Clin Oncol 2:194-200, 1984
9. Gobbi PG, Gendarini A, Crema A, et al: Serum albumin in Hodgkin's disease. Cancer 55:389-393, 1985
10. Haybittle JL, Easterling MJ, Bennet MH, et al: Review of British National Lymphoma Investigation studies of Hodgkin's disease and development of prognostic index. Lancet 1:967-972, 1985
11. Specht L, Nissen NI: Hodgkin's disease stages I and II with infradiaphragmatic presentation: A rare and prognostically unfavourable combination. Eur J Haematol 40:396-402, 1988
12. Specht L, Nordentoft AM, Cold S, et al: Tumor burden as the most important prognostic factor in early stage Hodgkin's disease. Relations to other prognostic factors and implications for choice of treatment. Cancer 61:1719-1727, 1988
13. Specht L, Lauritzen AF, Nordentoft AM, et al: Tumor cell concentration and tumor burden in relation to histopathologic subtype and other prognostic factors in early stage Hodgkin's disease. Cancer 65:2594-2601, 1990
14. MacLennan KA, Bennett MH, Tu A, et al: Relationship of histopathologic features to survival and relapse in nodular sclerosing Hodgkin's disease. A study of 1659 patients. Cancer 64:1686-1693, 1989
15. Pfreundschuh M, Lathan B, Loeffler M, et al: Recommendations for future clinical trials on Hodgkin's disease. Ann Oncol 3:101-104, 1992 (suppl 4)
16. Paglia MA, Lachner MJ, Hertz RE, et al: Surgical aspects and results of laparotomy and splenectomy in Hodgkin's disease. Am J Roentgenol 117:12-18, 1973
17. DeVita VT, Serpick AA, Carbone PP: Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 73:881-895, 1970
18. Bonadonna G, Zucali R, De Lena M, et al: Combination chemotherapy of Hodgkin's disease with Adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 36:252-259, 1975
19. Loeffler M, Hasenclever D: Probleme der Konzeption und Auswertung von Therapiestudien bei langer Behandlungsdauer, mittlerer CR-Rate und langer Überlebensdauer, in Selbmann HK, Dietz (eds): Medizinische Informationsverarbeitung und Epidemiologie im Dienste der Gesundheit, 32. Jahrestagung der GMDS, Tübingen, Germany, October 1987
20. Fuchs R, Loeffler M, Pfreundschuh M, et al: Prognosis of high dose chemotherapy/autologous bone marrow transplantation candidates not receiving this treatment after failure of primary therapy of Hodgkin's disease. Leuk Lymphoma (in press)
21. Proswitz LR, Roberts KB: Combined chemotherapy and radiotherapy for Hodgkin's disease. Oncology 6:113-128, 1992
22. Coia LR, Hanks GE: Complications from large field intermediate dose infradiaphragmatic radiation: An analysis of the Patterns of Care Outcome Studies for Hodgkin's disease and seminoma. Int J Radiat Oncol Biol Phys 15:29-35, 1988
23. Somers R, Henry-Amar, M, Meerwaldt JK, et al: Treatment strategy in Hodgkin's disease. Colloque INSERM vol 196. Paris, France, Libbey, 1990
24. Zittoun R, Audebert A, Hoerni B, et al: Extended versus involved fields irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin's disease. J Clin Oncol 3:207-214, 1985
25. Bonfante V, Santoro A, Viviani S, et al: ABVD plus radiotherapy (subtotal nodal vs involved field) in early stage Hodgkin's disease. Proc Am Soc Clin Oncol 13:373, 1994 (abstr 1262)